17959-06-7

Upstream product

• 1435-67-2 2,3,5-Trimethyl-4-(4-nitro-phenylazo)-phenol 
• 64-17-5 ethanol 
• 17302-53-3 4-(hydroxyimino)-2,3,6-trimethylcyclohexa-2,5-dien-1-one 
• 95-87-4 2,5-Dimethylphenol 
• 935-92-2 2,3,5-Trimethyl-1,4-benzoquinone 
• 855412-59-8 4-Hydroxyamino-2,3,6-trimethyl-phenol 
• 7647-01-0 hydrogenchloride 
• 67-56-1 methanol 
• 17959-07-8 2-Hydroxy-5-nitro-3,6-dimethyl-benzylchlorid 

Downstream Products

• 858244-36-7 formic acid-(4-hydroxy-2,3,5-trimethyl-anilide) 
• 935-92-2 2,3,5-Trimethyl-1,4-benzoquinone 
• 69477-72-1 N-(4-hydroxy-2,3,5-trimethylphenyl)acetamide 
• 2416-94-6 2,3,6-trimethylphenol 
• 185428-73-3 N-t-butoxycarbonyl-4-hydroxy-2,3,5-trimethylaniline 
• 202340-45-2 eflucimibe 
• 1299974-93-8 N-(2,3,5-trimethyl-4-hydroxyphenyl)-4-(4-fluorophenyl)-1,3-thiazole-2-amine 
• 1435-67-2 2,3,5-Trimethyl-4-(4-nitro-phenylazo)-phenol 
• 860192-03-6 6-methoxy-3-(4-methoxy-2,3,5-trimethyl-phenyl)-5,7,8-trimethyl-1,2,3,4-tetrahydro-quinazoline 
• 860192-75-2 6-methoxy-3-(4-methoxy-2,3,5-trimethyl-phenyl)-5,7,8-trimethyl-3,4-dihydro-quinazoline 
• 857554-09-7 acetic acid-(4-methoxy-2,3,5-trimethyl-anilide) 
• 120165-53-9 1-amino-4-methoxy-2,3,5-trimethylbenzene 
• 43109-09-7 4-(2,4-dinitro-phenylazo)-2,3,5-trimethyl-phenol 

Relevant academic research and scientific papers

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): STR1 [wherein: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulfur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethlyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and m is an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.

Treatment of arteriosclerosis and xanthoma

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-?1-(4-2'-pyridylphenyl)ethylideneaminooxy!-ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo?5,4-b!pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-?4-(6-methoxy-l-methylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-dione, 5-?4-(l-methylbenzimidazol-2-ylmethoxy)benzyl!-thiazolidine-2,4-dione and 5-?4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy) benzyllthiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

ρ-heteroatom-substituted phenols and uses thereof

The present invention provides an antiproliferative p-heteroatom-substituted phenol compound having the structure formula STR1 wherein m is 0 to 3, n is 0 to 4 when Het is nitrogen, wherein R is selected from the group consisting of hydrogen, alkyl, arylmethyl and acyl; R1 is alkyl; R2 is selected from the group consisting of hydrogen and alkyl; R3 is selected from the group consisting of alkyl and acyl when Het is nitrogen, R4 is selected from the group consisting of hydrogen and alkyl; R5 is selected from the group consisting of hydrogen and alkyl; and R6 and R7 are selected from the group consisting of hydrogen, alkyl and R6 and R7 together may represent oxygen. Also provided are various methods for the treatment of a pathological cell proliferative disease comprising administering to an animal) a pharmacologically and therapeutically effective dose of a pharmaceutical composition comprising a p-heteroatom-substituted phenols or an analog thereof.

Benzimidazole derivatives, their preparation and their therapeutic use

Compounds of formula (I): [in which: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl group; R represents hydrogen, alkyl, alkoxy, halogen, hydroxy, nitro, amino or aralkyl; and mis an integer from 1 to 5]; have valuable activity for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistance and diabetic complications.